Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Mo, Min Li ^a   Chen, Zhao ^a,b   Zhou, Hai Meng ^a   Li, Hui ^b   Hirata, Tomomi ^b,c   Jablons, David M ^b   He, Biao ^b  

^a TSINGHUA UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

E2A PBX1; Fusion gene; NSCLC

Indexed keywords

E2A PBX1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; K RAS PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA IN SITU; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMOSOME BREAKPOINTS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SEX FACTORS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877853271     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-29     Document Type: Article

References (31)

1. Cancer statistics, 2008. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, Stebbings LA, Leroy C, Edkins S, Hardy C, Nat Genet 2008 40 722 729 10.1038/ng.128 18438408 (Pubitemid 351748860)
3. Oncogenes and cancer. Croce CM, N Engl J Med 2008 358 502 511 10.1056/NEJMra072367 18234754 (Pubitemid 351185806)
4. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Mitelman F, Johansson B, Mertens F, Nat Genet 2004 36 331 334 10.1038/ng1335 15054488 (Pubitemid 38437252)
5. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, Cleary ML, Cell 1990 60 535 545 10.1016/0092-8674(90)90657-Z 1967982 (Pubitemid 20083810)
6. Site-specific translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Wiemels JL, Leonard BC, Wang Y, Segal MR, Hunger SP, Smith MT, Crouse V, Ma X, Buffler PA, Pine SR, Proc Natl Acad Sci USA 2002 99 15101 15106 10.1073/pnas.222481199 12415113 (Pubitemid 35334616)
7. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Dedera DA, Waller EK, LeBrun DP, Sen-Majumdar A, Stevens ME, Barsh GS, Cleary ML, Cell 1993 74 833 843 10.1016/0092-8674(93)90463-Z 8104101 (Pubitemid 23270603)
8. Oncoprotein E2A-Pbx1 immortalizes a myeloid progenitor in primary marrow cultures without abrogating its factor-dependence. Kamps MP, Wright DD, Oncogene 1994 9 3159 3166 7936638 (Pubitemid 24338442)
9. Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable. Monica K, LeBrun DP, Dedera DA, Brown R, Cleary ML, Mol Cell Biol 1994 14 8304 8314 7969166 (Pubitemid 24373579)
10. E2a-Pbx1 induces aberrant expression of tissue-specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts. Fu X, Kamps MP, Mol Cell Biol 1997 17 1503 1512 9032278 (Pubitemid 27097380)
11. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML, Blood 1991 77 687 693 1671560
12. The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials. Kamps MP, Look AT, Baltimore D, Genes Dev 1991 5 358 368 10.1101/gad.5.3.358 1672117 (Pubitemid 21905959)
13. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. McWhirter JR, Goulding M, Weiner JA, Chun J, Murre C, Development 1997 124 3221 3232 9310317 (Pubitemid 27440437)
14. Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C, Proc Natl Acad Sci USA 1999 96 11464 11469 10.1073/pnas.96.20.11464 10500199 (Pubitemid 29487403)
15. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Smith KS, Chanda SK, Lingbeek M, Ross DT, Botstein D, van Lohuizen M, Cleary ML, Mol Cell 2003 12 393 400 10.1016/S1097-2765(03)00277-6 14536079 (Pubitemid 37238926)
16. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Cancer Res 2007 67 5667 5672 10.1158/0008-5472.CAN-06-4229 17575133 (Pubitemid 46984998)
17. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Sonobe M, Manabe T, Wada H, Tanaka F, Br J Cancer 2005 93 355 363 10.1038/sj.bjc.6602707 16052218 (Pubitemid 43080038)
18. Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. Sonobe M, Manabe T, Wada H, Tanaka F, J Mol Diagn 2006 8 351 356 10.2353/jmoldx.2006.050132 16825508 (Pubitemid 44063812)
19. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2011 6 244 285 10.1097/JTO. 0b013e318206a221
20. A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. Kim IJ, Kang HC, Shin Y, Park HW, Jang SG, Han SY, Lim SK, Lee MR, Chang HJ, Ku JL, J Hum Genet 2004 49 591 595 10.1007/s10038-004-0193-9 15368100 (Pubitemid 40392420)
21. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
22. K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer. Sagawa M, Saito Y, Fujimura S, Linnoila RI, Br J Cancer 1998 77 720 723 10.1038/bjc.1998.118 9514049 (Pubitemid 28077458)
23. Real-time reverse transcription polymerase chain reaction detection and quantification of t(1;19) (E2A-PBX1) fusion genes associated with leukaemia. Curry JD, Glaser MC, Smith MT, Br J Haematol 2001 115 826 830 10.1046/j.1365-2141.2001.03190.x 11843816 (Pubitemid 34042900)
24. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM, Oncogene 2005 24 5396 5400 10.1038/sj.onc.1208568 16007226 (Pubitemid 43080110)
25. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R, Br J Cancer 2004 91 355 358 15188009 (Pubitemid 39037083)
26. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Cancer Res 2005 65 1642 1646 10.1158/0008-5472. CAN-04-4235 15753357 (Pubitemid 40478587)
27. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, Roberts JR, Carbone DP, J Natl Cancer Inst 2000 92 1355 1357 10.1093/jnci/92.16.1355 10944559 (Pubitemid 30660597)
28. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Nature 2007 448 561 566 10.1038/nature05945 17625570 (Pubitemid 47206930)
29. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Nature 2007 448 595 599 10.1038/nature06024 17671502 (Pubitemid 47206938)
30. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Science 2005 310 644 648 10.1126/science.1117679 16254181 (Pubitemid 41528150)
31. Current concepts in bronchioloalveolar carcinoma biology. Raz DJ, He B, Rosell R, Jablons DM, Clin Cancer Res 2006 12 3698 3704 10.1158/1078-0432.CCR- 06-0457 16778095 (Pubitemid 44000249)